Last reviewed · How we verify
HS-10516
At a glance
| Generic name | HS-10516 |
|---|---|
| Sponsor | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom (PHASE1, PHASE2)
- Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma (PHASE1, PHASE2)
- A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors (PHASE1)
- A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HS-10516 CI brief — competitive landscape report
- HS-10516 updates RSS · CI watch RSS
- Jiangsu Hansoh Pharmaceutical Co., Ltd. portfolio CI